Cadrenal Therapeutics, Inc. Common Stock (CVKD)
$
11
-0.01 (-0.09%)
Key metrics
Financial statements
Free cash flow per share
-5.7871
Market cap
22.8 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
3.0160
Income quality
0.8218
Average inventory
0
ROE
-2.7952
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company focused on advancing its innovative therapy, Tecarfarin, which has received orphan drug designation for preventing systemic thromboembolism of cardiac origin in patients suffering from end-stage renal disease and atrial fibrillation. The company was established in 2022 and is based in Ponte Vedra, Florida. In its financial performance, the net total of other income and expenses is $309,251.00 reflecting non-core financial activities that could impact overall profitability. The income before tax ratio stands at 0.00 indicating the pre-tax margin achieved by the company during its operations. Investors will find that the company's stock is identified with the symbol 'CVKD' in the market, providing a straightforward way to track its performance. Additionally, the diluted EPS is -$8.73 which takes into account any potential share dilution that might affect earnings per share. It is noteworthy that the company incurred an interest expense of $0.00 which reflects its commitments to debt servicing and can influence cash flow management. Looking at the investment landscape, the stock is affordable at $13.17 making it suitable for budget-conscious investors who are exploring opportunities in the biopharmaceutical sector. However, it exhibits a low average trading volume of 30,058.00 indicating lower market activity which may impact liquidity and volatility. With a market capitalization of $22,828,432.00 the company is classified as a small-cap player within its industry. Cadrenal is a key player in the Biotechnology industry, where it contributes significantly to the overall market landscape by driving innovation and therapeutic advancements. Furthermore, it belongs to the Healthcare sector, a vital part of the economy, and is dedicated to fostering growth and development in its field.
Is Cadrenal Therapeutics, Inc. Common Stock (CVKD) a good investment?
Investing in Cadrenal Therapeutics, Inc. Common Stock (CVKD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Cadrenal Therapeutics, Inc. Common Stock (CVKD)'s stock forecast?
Analysts predict Cadrenal Therapeutics, Inc. Common Stock stock to fluctuate between $8.12 (low) and $22.90 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cadrenal Therapeutics, Inc. Common Stock's market capitalization?
As of 2025-12-12, Cadrenal Therapeutics, Inc. Common Stock's market cap is $22,828,432, based on 2,075,312 outstanding shares.
How does Cadrenal Therapeutics, Inc. Common Stock compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Cadrenal Therapeutics, Inc. Common Stock has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock?
To buy Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CVKD. Place an order (Market, Limit, etc.).
What is the best time to invest in Cadrenal Therapeutics, Inc. Common Stock?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Cadrenal Therapeutics, Inc. Common Stock stock ever split?
Cadrenal Therapeutics, Inc. Common Stock's last stock split was 1:15 on 2024-08-20.
How did Cadrenal Therapeutics, Inc. Common Stock perform in the last earnings report?
Revenue: $0 | EPS: -$8.73 | Growth: -9.35%.
Where can I find Cadrenal Therapeutics, Inc. Common Stock's investor relations reports?
Visit https://www.cadrenal.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cadrenal Therapeutics, Inc. Common Stock?
You can explore historical data from here
What is the all-time high and low for Cadrenal Therapeutics, Inc. Common Stock stock?
All-time high: $101.25 (2023-01-20) | All-time low: $5.40 (2024-04-10).
What are the key trends affecting Cadrenal Therapeutics, Inc. Common Stock stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
2 days ago
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ: CVKD ) entered the back half of the year with a calm, almost surgical approach to building out its foundation. While most microcaps lean on noise to stay visible, Cadrenal has let its work do the lifting.
accessnewswire.com
2 days ago
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused.
globenewswire.com
3 days ago
PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Veralox”). The acquisition immediately strengthens Cadrenal's pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. This acquisition addresses yet another underserved therapeutic opportunity in the $40 billion global anticoagulation market.
globenewswire.com
13 days ago
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D.
globenewswire.com
25 days ago
PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced its Chairman and Chief Executive Officer, Quang X. Pham, received the prestigious BioFlorida, Inc. “Executive of the Year Award,” at the recently held Florida Innovation Conference, powered by BioFlorida, in Orlando.
globenewswire.com
a month ago
PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian.
defenseworld.net
a month ago
Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($1.55) per share for the quarter. Parties may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call
globenewswire.com
2 months ago
PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.
See all news
